These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39250652)

  • 1. Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    Lazzaro A; Vai D; Barco A; Stroffolini G; Pirriatore V; Guastamacchia G; Nigra M; Ghisetti V; Tettoni MC; Noce G; Giaccone C; Trunfio M; Trentalange A; Bonora S; Di Perri G; Calcagno A
    J Acquir Immune Defic Syndr; 2024 Oct; 97(2):180-191. PubMed ID: 39250652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen.
    Stroffolini G; Lazzaro A; Barco A; Pirriatore V; Vai D; Giaccone C; Nigra M; Atzori C; Trunfio M; Bonora S; Di Perri G G; Calcagno A
    J Neuroimmune Pharmacol; 2023 Dec; 18(4):551-562. PubMed ID: 37906406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
    Barber TJ; Imaz A; Boffito M; Niubó J; Pozniak A; Fortuny R; Alonso J; Davies N; Mandalia S; Podzamczer D; Gazzard B
    J Neurovirol; 2018 Feb; 24(1):98-105. PubMed ID: 29280108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
    Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
    AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
    Podzamczer D; Imaz A; Lopez-Lirola A; Knobel H; Masiá M; Fanciulli C; Hernández C; Lagarde M; Gutierrez A; Curran A; Morano L; Montero-Alonso M; Troya J; Rigo R; Casadellà M; Navarro-Alcaraz A; Ardila F; Parera M; Bernal E; Echeverria P; Estrada V; Hidalgo-Tenorio C; Macias J; Prieto P; Portilla J; Valencia E; Vivancos MJ; Rivero A
    J Antimicrob Chemother; 2023 Nov; 78(11):2696-2701. PubMed ID: 37725999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study.
    Van Hemelryck S; Van Landuyt E; Hufkens V; Vanveggel S
    Antivir Ther; 2024 Apr; 29(2):13596535241248282. PubMed ID: 38725258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
    Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
    Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
    Ranzenigo M; Gianotti N; Galli L; Poli A; Mastrangelo A; Bruzzesi E; Chiurlo M; Nozza S; Bossolasco S; Spagnuolo V; Mancusi D; Termini R; Carini E; Lazzarin A; Castagna A
    Drug Des Devel Ther; 2022; 16():1975-1982. PubMed ID: 35783200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognition with maraviroc compared with tenofovir in HIV.
    Robertson KR; Miyahara S; Lee A; Brown TT; Chan ES; Berzins B; Rusin D; Eron JJ; Taiwo BO;
    AIDS; 2016 Sep; 30(15):2315-21. PubMed ID: 27333088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study.
    Force G; Ghout I; Ropers J; Carcelain G; Marigot-Outtandy D; Hahn V; Darchy N; Defferriere H; Bouaziz-Amar E; Carlier R; Dorgham K; Callebert J; Peytavin G; Delaugerre C; de Truchis P;
    J Antimicrob Chemother; 2021 Feb; 76(3):743-752. PubMed ID: 33179033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Deeks ED
    Drugs; 2018 Jul; 78(10):1013-1024. PubMed ID: 29915897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.
    Robertson K; Landay A; Miyahara S; Vecchio A; Masters MC; Brown TT; Taiwo BO
    J Neurovirol; 2020 Feb; 26(1):107-113. PubMed ID: 31468473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.
    Yuan NY; Kaul M
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):90-112. PubMed ID: 31385157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.
    Mills A; Garner W; Pozniak A; Berenguer J; Speck RM; Bender R; Nguyen T
    Patient; 2015 Aug; 8(4):359-71. PubMed ID: 26045359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study.
    Tiraboschi J; Hamzah L; Teague A; Kulasegaram R; Post F; Jendruleck I; Murray T; Fox J
    AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1198-1201. PubMed ID: 27216134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
    Orkin C; Eron JJ; Rockstroh J; Podzamczer D; Esser S; Vandekerckhove L; Van Landuyt E; Lathouwers E; Hufkens V; Jezorwski J; Opsomer M;
    AIDS; 2020 Apr; 34(5):707-718. PubMed ID: 31833849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.
    Ellis RJ; Letendre S; Vaida F; Haubrich R; Heaton RK; Sacktor N; Clifford DB; Best BM; May S; Umlauf A; Cherner M; Sanders C; Ballard C; Simpson DM; Jay C; McCutchan JA
    Clin Infect Dis; 2014 Apr; 58(7):1015-22. PubMed ID: 24352352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.